Guo 2009.
Methods | Parallel group, 3‐arm trial, comparing sertraline plus routine care versus routine care versus acupuncture plus routine care. We are using the sertraline plus routine care versus routine care in this review Aim: to treat depression Analysis: according to allocated treatment |
|
Participants | Country: China Setting: unknown Stroke criteria: first ever stroke, clinical diagnosis plus relevant lesion on imaging, age ≥ 60 years old Depression criteria: HAMD score ≥ 8, no depression prior to stroke Treatment: 40 people, mean age 67.6 ± 12.43 years, 23 men Control: 40 people, mean age 64.5 ± 12.07 years, 22 men Exclusions: psychiatric disorders or family psychiatric disorders, severe cognitive impairment, global aphasia, sensory aphasia, apraxia, severe cardiac, hepatic, renal, lung or other severe somatic disorder, consciousness disturbance, severe deafness, family or patient unable to comply |
|
Interventions | Treatment: sertraline 50 mg daily plus stroke care (acute, secondary prevention, rehabilitation and psychotherapy) Control: stroke care (acute, secondary prevention, rehabilitation and psychotherapy) Duration of treatment: 6 weeks Duration of follow‐up: (treatment end to study end): 6 months |
|
Outcomes | HAMD NIHSS FIM (reported cognition and mobility scores only) SF‐36 AEs not reported |
|
Funding source | Funded by a local scientific academic fund | |
Notes | − | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Random‐number table |
Allocation concealment (selection bias) | Unclear risk | Not described |
Blinding of participants and personnel (performance bias) All outcomes | High risk | No placebo |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | Outcome assessor blind |
Incomplete outcome data (attrition bias) All outcomes | Low risk | No dropouts, analysed by allocated treatment |
Selective reporting (reporting bias) | Unclear risk | No protocol |
Other bias | Low risk | No obvious risk, balance baseline |